2022
MemAID: Memory advancement with intranasal insulin vs. placebo in type 2 diabetes and control participants: a randomized clinical trial
Novak V, Mantzoros C, Novak P, McGlinchey R, Dai W, Lioutas V, Buss S, Fortier C, Khan F, Aponte Becerra L, Ngo L. MemAID: Memory advancement with intranasal insulin vs. placebo in type 2 diabetes and control participants: a randomized clinical trial. Journal Of Neurology 2022, 269: 4817-4835. PMID: 35482079, PMCID: PMC9046533, DOI: 10.1007/s00415-022-11119-6.Peer-Reviewed Original ResearchConceptsIntranasal insulinCerebral blood flowPlasma insulinBlood flowType 2 diabetes mellitusVerbal memorySerious adverse eventsDouble-blinded trialRandomized clinical trialsType 2 diabetesAge-related functional declineHOMA-IRAdverse eventsDiabetes mellitusPrimary outcomeWeeks treatmentHypoglycemic episodesT2DM participantsControl placeboPreliminary safetyClinical trialsFunctional declineLong-term effectsBackgroundThis studyBetter executive function
2021
193-OR: Memory Advancement with Intranasal Insulin in Type 2 Diabetes: Randomized Control Trial
NOVAK V, MANTZOROS C, NOVAK P, MCGLINCHEY R, DAI W, LIOUTAS V, BUSS S, FORTIER C, KHAN F, BECERRA L, NGO L. 193-OR: Memory Advancement with Intranasal Insulin in Type 2 Diabetes: Randomized Control Trial. Diabetes 2021, 70 DOI: 10.2337/db21-193-or.Peer-Reviewed Original ResearchIntranasal insulinSpouse/partnerT2DM-related cognitive impairmentType 2 diabetes mellitusPhase 2 trialSignificant adverse eventsRisk of dementiaDual-task walkingNovo NordiskPseudo-continuous arterial spin labelingArterial spin labelingWorld Health OrganizationAdvisory PanelAdverse eventsDiabetes mellitusPrimary outcomeDual taskT2DM participantsKidney diseaseBlind trialControl trialDrug AdministrationType 2Cognitive impairmentT2DM